GLP-1

CagriSema (Cagrilintide + Semaglutide): The Next-Gen Weight Loss Combo Explained

Medici

30 Apr 2026 — 5 min read

A new era in obesity medicine is taking shape — and it goes by the name CagriSema. Developed by Novo Nordisk, CagriSema combines two distinct peptide therapies — cagrilintide, a long-acting amylin analogue, and semaglutide, the active ingredient in Ozempic and Wegovy — into a single weekly injection. The result? Phase 3 clinical trial data showing average weight loss of over 20%, surpassing anything seen with either drug used alone.

For anyone following the GLP-1 landscape, this is a significant development. While tirzepatide (Mounjaro/Zepbound) expanded on semaglutide by adding a GIP receptor pathway, CagriSema takes a fundamentally different approach — layering an entirely separate hormonal system on top of the GLP-1 mechanism. Understanding how and why this works requires a look at the biology of amylin.

What Is Amylin — And Why Does It Matter for Weight Loss?

Amylin is a peptide hormone co-secreted alongside insulin by the beta cells of the pancreas, primarily in response to meals. In healthy individuals, amylin plays three key metabolic roles:

Appetite suppression: Amylin signals to the area postrema and brainstem, reducing hunger signals between meals and after eating.
Gastric emptying delay: It slows the transit of food from the stomach into the small intestine, extending fullness sensations by 40–50% compared to baseline.
Glucagon suppression: It inhibits post-meal glucagon secretion, reducing glucose spikes after eating.

Critically, amylin deficiency is common in both obesity and type 2 diabetes. Beta cell dysfunction reduces amylin output, creating a state where appetite signals are impaired and gastric emptying is too fast — both conditions that promote weight gain and metabolic dysfunction.

Cagrilintide was designed specifically to restore and amplify this amylin signaling. Unlike the only previous amylin analogue (pramlintide, marketed as Symlin), cagrilintide is engineered for once-weekly dosing through albumin binding — the same mechanism that gives semaglutide its long duration of action.

How CagriSema Works: A Dual-Pathway Mechanism

What makes CagriSema exceptional is that cagrilintide and semaglutide act on different receptors in different brain regions. This is not redundancy — it's genuine complementarity.

Semaglutide (GLP-1 receptor agonist):

Activates GLP-1 receptors in the hypothalamus, arcuate nucleus, and vagal nerve
Reduces appetite and food intake via the hypothalamic reward and satiety circuits
Slows gastric emptying and improves insulin secretion

Cagrilintide (amylin receptor agonist):

Activates amylin receptors (AMY1–3) in the area postrema and nucleus of the solitary tract in the brainstem
Independently suppresses appetite through a CNS pathway semaglutide does not primarily target
Further slows gastric emptying through a distinct physiological mechanism
Suppresses post-meal glucagon secretion

Because these pathways converge on appetite and metabolism from different directions, combining them produces additive — and in some analyses, synergistic — effects. This is the mechanistic foundation behind why CagriSema outperforms either drug in isolation.

REDEFINE Trials: The Clinical Evidence

The REDEFINE clinical trial program — specifically REDEFINE 1 and REDEFINE 2 — provided the pivotal phase 3a evidence for CagriSema's efficacy and safety.

REDEFINE 1: Participants Without Type 2 Diabetes

Design: 3,417 adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one obesity-related complication (excluding T2D). Duration: 68 weeks. CagriSema 2.4 mg weekly vs. semaglutide alone, cagrilintide alone, or placebo.

Key weight loss results:

CagriSema: −20.4% mean body weight change (treatment-adherent analysis: −22.7%)
Semaglutide alone: −14.9%
Cagrilintide alone: −11.5%
Placebo: −3.0%

Responder analysis:

91.9% of CagriSema participants achieved ≥5% weight loss (vs. 31.5% placebo)
60% achieved ≥20% weight loss
23% achieved ≥30% weight loss
40.4% achieved ≥25% weight loss in the adherent population

Additional metabolic benefits:

Significant reductions in systolic blood pressure, waist circumference, and triglycerides
88% of participants with prediabetes at baseline returned to normoglycemia

REDEFINE 2: Participants With Type 2 Diabetes

Design: 1,206 adults with BMI ≥27 and glycated hemoglobin (HbA1c) between 7–10%. Duration: 68 weeks.

Key results:

CagriSema: −13.7% mean body weight change
Placebo: −3.4%

Glycemic control:

73.5% of CagriSema recipients achieved HbA1c ≤6.5% versus 15.9% with placebo
Low incidence of hypoglycemia observed throughout the trial

The weight loss in REDEFINE 2 is lower than REDEFINE 1 — a pattern consistent with other GLP-1 therapies, where type 2 diabetes blunts the magnitude of weight loss response, likely due to altered beta cell function and insulin resistance.

CagriSema vs. Semaglutide vs. Tirzepatide: How Does It Stack Up?

To put CagriSema's results in context, it helps to compare them against the current best-in-class options:

The comparison table (GLP-1 only semaglutide ~15% weight loss; GLP-1+GIP tirzepatide ~22.5%; GLP-1+Amylin CagriSema 20.4–22.7%) reveals that CagriSema and tirzepatide produce broadly similar weight loss outcomes — both significantly exceeding semaglutide alone. However, they work through entirely different mechanisms: tirzepatide adds GIP receptor agonism to GLP-1, while CagriSema adds amylin receptor agonism.

This distinction matters clinically. Patients who plateau on tirzepatide (or who cannot tolerate it) may respond differently to CagriSema. Additionally, CagriSema's amylin-mediated glucagon suppression provides a complementary glycemic control mechanism in T2D that may translate to unique clinical benefits in specific patient populations.

Side Effects and Safety Profile

CagriSema's safety profile is consistent with the broader GLP-1 drug class, with gastrointestinal effects being the dominant consideration.

Common adverse effects:

Gastrointestinal: Nausea, vomiting, diarrhea, constipation — reported in approximately 79.6% of CagriSema participants vs. 39.9% with placebo in REDEFINE 1
The majority of GI events were transient, mild to moderate in severity, and most frequent during dose escalation

Serious adverse events: Rates were low and comparable to placebo. No new or unexpected safety signals emerged from either REDEFINE trial.

Low hypoglycemia risk: Despite significant glycemic improvements in T2D patients, hypoglycemia incidence was low — an important distinguishing feature from older diabetes medications such as sulfonylureas.

The GI side effect burden is higher than semaglutide alone (79.6% vs. approximately 40–44% in the STEP trials), expected given the additive gastric-slowing effects of both agents combined. Gradual dose titration over several months is the primary management strategy.

FDA Status and When CagriSema Might Be Available

In December 2025, Novo Nordisk filed a New Drug Application (NDA) with the FDA for CagriSema — marking the first regulatory submission for a once-weekly GLP-1 and amylin analogue combination therapy for weight management.

Under the FDA's standard 10-month review process, a decision is expected around October 2026. If approved, CagriSema would launch as a new branded prescription medication. As a novel approved drug (not currently in shortage), it would not be available through compounding pharmacies at launch.

As of April 2026, CagriSema is not available for prescription use outside of clinical trial settings.

What CagriSema Means for the Future of Obesity Medicine

CagriSema's emergence signals a broader trend: the future of obesity pharmacotherapy is increasingly about multi-pathway hormone targeting. Just as HIV treatment evolved from single antiretrovirals to combination regimens, obesity treatment is moving toward combinations that address multiple hormonal deficits simultaneously.

The amylin pathway has long been underexploited. Pramlintide (Symlin), the only previously approved amylin analogue, required three-times-daily injections and produced modest weight loss — severely limiting its practical use. Cagrilintide's once-weekly profile solves the adherence problem, and its combination with semaglutide leverages the complementary receptor geography of the brainstem and hypothalamus to produce outcomes that neither agent achieves alone.

Looking ahead, the success of CagriSema is likely to accelerate development of triple-action combinations — GLP-1 + amylin + GIP, GLP-1 + amylin + glucagon receptor agonism, or even GLP-1 + amylin + GIP + glucagon (the "quad-agonist" concept). The biological logic is established, and REDEFINE proves the principle at scale.

Key Takeaways

CagriSema combines cagrilintide (amylin analogue) and semaglutide (GLP-1 agonist) in a once-weekly injection
REDEFINE 1 showed −20.4% average weight loss (−22.7% adherent) — significantly better than semaglutide alone (−14.9%)
60% of non-diabetic participants achieved ≥20% weight loss; 23% achieved ≥30%
In T2D patients, 73.5% achieved HbA1c ≤6.5% with low hypoglycemia risk
GI side effects are common (79.6%) but manageable with gradual dose titration
Novo Nordisk filed for FDA approval in December 2025; decision expected approximately October 2026
Weight loss outcomes comparable to tirzepatide, but through a mechanistically distinct pathway